We are very excited to finally give customers a choice when it comes to dual luciferase assays. Not only do we support the complete solution for readers, software and assays, we offer better pricing too.
Sunnyvale, California (PRWEB) April 18, 2017
Molecular Devices announced today an addition to its assay kits portfolio with the launch of the new SpectraMax® DuoLuc™ Reporter Assay Kit enabling highly sensitive quantitation of both firefly and Renilla luciferases in mammalian cells.
Reporter gene assays are an important tool for researchers to monitor cellular events associated with gene expression, gene regulation, and signal transduction. Firefly luciferase, one of the most commonly used reporters, produces light by catalyzing a bioluminescence reaction that oxidizes D-luciferin in the presence of oxygen and ATP. Renilla luciferase catalyzes coelenterazine oxidation to produce light. Due to the difference in substrate requirements, it is possible to measure the activity of both luciferases in a single sample through sequential addition of the substrates. The result is a convenient assay with two readouts that can be normalized to each other to provide more complete information about a cellular pathway or event.
The SpectraMax DuoLuc Reporter Assay Kit detects firefly and Renilla luciferase expression in as few as ten cells per well, improves accuracy of results by normalizing reporter expression to a control, and speeds time to results with a preconfigured SoftMax® Pro Software protocol optimized for luminescence microplate readers with injectors.
Scott Greenstone, Director of Reagents at Molecular Devices, commented: “We are very excited to finally give customers a choice when it comes to dual luciferase assays. Not only do we support the complete solution for readers, software and assays, we offer better pricing too.”
About Molecular Devices, LLC
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.
For more information, visit: